Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

The approval is the strongest challenge yet to Pfizer’s pneumococcal vaccine franchise, led by its 20-valent Prevnar 20 shot, which generated $6.4 billion in sales last year from use for ...

For prevention of IPD, the National Advisory Committee on Immunization (NACI) has recommended the 23-valent polysaccharide pneumococcal vaccine, PNEU-P-23, for adults 65 years of age and older and ...